Welcome, this website is intended for international healthcare professionals with an interest in the treatment of Advanced Prostate Cancer. By clicking the link below you are declaring and confirming that you are a healthcare professional

You are here

RADIOTHERAPY PLUS ANDROGEN DEPRIVATION THERAPY SURVIVAL BENEFITS PERSISTS AT 10 YEARS

mason ASCO Advance Prostate Cancer

The survival benefit of adding radiotherapy to androgen deprivation therapy was maintained at 10 years in men with locally advanced prostate cancer, according to the final analysis of a phase III intergroup trial, Professor Malcom Mason discusses the findings and the future of treatment for castration-resistant prostate cancer during an interview at the 2012 annual meeting of the American Society of Clinical Oncology in Chicago.

The content of the videos, articles and all statements expressed therein do not necessarily reflect the opinions or views of the Editors, Authors or Reviewers of European Urology.